Catalyst Dossier · compiled by CeliA 🧫
Sanofi (SNYNF)
Biotechnology · market cap $99.8B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Sanofi (SNYNF) is a large-cap global biopharmaceutical company with approximately 74,846 employees and a market capitalization of ~$99.8B. The company carries a broad, diversified pipeline spanning Phase 2–3 across immunology, rare diseases, vaccines, oncology, and cardiometabolic indications. Near-term catalysts are concentrated in fitusiran (Phase 3, imp 9/10, August 2026) and PCV21 (Phase 3, imp 9/10, January 2027), alongside several Phase 2 readouts.
The catalyst path
- 2026-10-30 (est.)Phase 2 · venglustat (GZ402671)imp 7/10
- 2026-12-23 (est.)Phase 2 · frexalimabimp 7/10
- 2027-01-07 (est.)Phase 3 · PCV21imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Teriflunomide (HMR1726) | Phase 3 | Multiple Sclerosis |
| DTaP-IPV-HB-PRP~T vaccine | Phase 3 | Diphtheria |
| SAR3419 | Phase 2 | Diffuse Large B-cell Lymphoma |
| XRP0038 (NV1FGF) | Phase 2 | Peripheral Arterial Occlusive Disease |
| Insulin glargine/lixisenatide Fixed Ratio Combination | Phase 3 | Type 2 Diabetes |
| Irbesartan | Phase 3 | Atrial Fibrillation |
| Split, Inactivated, Trivalent Influenza Vaccine | Phase 2 | Orthomyxoviridae Infection |
| Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | Phase 2 | Systemic Sclerosis |
| Levofolinate | Phase 2 | Colorectal Cancer Metastatic |
| teriflunomide HMR1726 | Phase 3 | Multiple Sclerosis |
| Mitoxantrone | Phase 3 | Prostatic Neoplasms |
| rhIDU (recombinant human-Alpha-L-Iduronidase) | Phase 3 | Mucopolysaccharidosis I |
| escitalopram | Phase 3 | Major Depressive Disorder |
| SR121463B | Phase 3 | Inappropriate ADH Syndrome |
| Olipudase alfa | Phase 3 | Sphingomyelin Lipidosis |
| Myozyme | Phase 3 | Glycogen Storage Disease Type II |
| Itepekimab SAR440340 | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Insulin glulisine QD | Phase 3 | Type 2 Diabetes |
| G-CSF Plus Plerixafor | Phase 2 | Lymphoma, Non-Hodgkin |
| frexalimab | Phase 2 | Focal Segmental Glomerulosclerosis |
Price & technical context
3-month
-5.7%
6-month
-5.5%
12-month
-9.7%
52-wk range
$81.29–$104.97
vs 50-day MA
-4.2%
vs 200-day MA
-7.4%
Realized vol
33.3%
Max drawdown
-33.1%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SNYNF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.